title: Pharmaceutical approval update.
abstract: Obinutuzumab (Gazyva) for chronic lymphocytic leukemia; ibrutinib (Imbruvica) for mantle-cell lymphoma; and sofosbuvir (Sovaldi) for chronic hepatitis C infection.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg